Chemomab Therapeutics (NASDAQ:CMMB) Downgraded by Zacks Investment Research to Hold

Chemomab Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Chemomab Therapeutics Downgraded by Zacks Investment Research on 10/18/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Chemomab Therapeutics (NASDAQ:CMMB) Downgraded by Zacks Investment Research to Hold